On Tuesday, Emergent BioSolutions Inc. (NYSE:EBS) reported second-quarter 2024 sales of $254.7 million, down 25% year over year, beating the consensus of $190 million. The company reported an adjusted EPS loss of $(2.32), more than double the $(1.05) reported a year ago, missing the consensus of $(0.94). Revenues from Narcan (naloxone HCl) Nasal Spray decreased 10% to $120 million, primarily driven by an unfavorable price and volume mix in 2024 to U.S. public interest channels and lower Canadian market sales, partially offset by higher sales of over-the-counter Narcan through wholesaler channels, which launched in the third quarter of 2023. Also ...